BioScrip completes Critical Homecare Solutions acquisition
ELMSFORD, N.Y. BioScrip has created one of the largest home care providers in the United States with the completion of its acquisition of Critical Homecare Solutions, the specialty pharmacy company announced Thursday.
The acquisition, announced in late January, gives BioScrip a total of 33 community service centers, 61 specialty infusion pharmacies, 33 nursing locations and three mail-order pharmacies. BioScrip paid around $348 million in cash and stock while also issuing 3.4 million warrants with a $10 exercise price and a five-year term to CHS stockholders.
“The combination of CHS and BioScrip represents a significant step forward in our strategy to become the clinical leader in the management of the chronically ill across all drug-delivery technologies,” BioScrip chairman and CEO Richard Friedman said.
FDA to have Genzyme plant inspected, reviewed
CAMBRIDGE, Mass. Genzyme Corp. will have to submit to inspections of one of its plants by the Food and Drug Administration and pay fees to the agency under a consent decree, the biotechnology company said Wednesday.
The FDA will likely hire a third party to inspect and review Genzyme’s plant in the Boston neighborhood of Allston for an extended period of time to ensure its compliance with accepted manufacturing standards. Genzyme will also have to pay the FDA for the inspections, and may have to pay other fees as well.
The action comes as a result of an incident in June 2009, when the company detected a virus that inhibits cell growth in one of the containers it uses to manufacture drugs; the virus, vesivirus 2117, is not known to cause human infection. The company said the virus was the cause of declines in productivity at two of its plants, including Allston, in 2008, and was likely introduced via a nutrient used in the manufacturing process.
In November 2009, the company found particulate matter in supplies of drugs from the Allston plant, particularly the Gaucher disease drug Cerezyme (imiglucerase), the Fabry disease drug Fabrazyme (agalsidase beta), the Pompe disease drug Myozyme (alglucosidase alfa), the mucopolysaccharidosis treatment Aldurazyme (laronidase) and the thyroid disease drug Thyrogen (thyrotropin alfa).
The drug maker said it expected shipments of the Cerezyme, Fabrazyme and Myozyme, which are manufactured at the Allston plant, to continue uninterrupted.
SVP product development and clinical operations
HAYWARD, Calif. A company that develops drugs for inflammatory diseases has made a new executive appointment.
Anthera Pharmaceuticals announced that it hired Georgina Kilfoil for the newly-created position of SVP product development and clinical operations. Prior to working for Anthera, Kilfoil was a consultant at InClin and VP alliances and project management at Peninsula Pharmaceuticals.
“Georgina brings over 18 years of project management and clinical research expertise, making her a valuable and welcome addition to our senior management team,” Anthera president and CEO Paul Truex said in a statement.